积极和被动心脏指数作为左心室辅助器件植入后结果的互补预测指标
Wing Sum Vincy Tam1, Rolando Calderon1, Shuyang Lu1
1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
The Journal of thoracic and cardiovascular surgery
|September 10, 2025
概括
新的心脏指数,主动心脏指数 (ActCI) 和被动心脏指数 (PasCI),预测了接受左心室辅助装置 (LVAD) 的患者的生存率和右心室衰竭. 与传统措施相比,这些指标提供了更好的风险分层.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 生物医学工程 生物医学工程
背景情况:
- 左心室辅助器械 (LVAD) 治疗旨在减少右心室 (RV) 衰竭并改善生存率.
- 传统的指标可能无法完全捕捉LVAD治疗的生理复杂性.
- 该研究引入了主动心脏指数 (ActCI) 和被动心脏指数 (PasCI) 作为新的预后工具.
研究的目的:
- 评估ActCI和PasCI在LVAD植入后预测结果的预后效用.
- 将ActCI和PasCI的有效性与肺动脉脉动指数和RV中风工作指数等传统指标进行比较.
主要方法:
- 对399名接受初级持续流动LVAD植入的患者进行了回顾性分析.
- 从手术前右心脏导管数据计算LVAD前的ActCI和PasCI.
- 确定最佳生存值,使用线分析和与现有指数进行比较.
主要成果:
- 高ActCI (>0.903) 与更好的生存率相关,而高PasCI (>0.778) 预测了更差的生存率.
- 低ActCI与增加RV衰竭,透析,肝功能障碍和住院死亡率有关.
- 更高的PasCI与透析,呼吸衰竭,肝功能障碍,胃肠道出血和住院死亡率的增加有关.
结论:
- ActCI和PasCI独立地预测LVAD后的生存率和RV失败.
- 这些新型指数与肺动脉脉动指数和RV中风工作指数相比,表现优越.
- ActCI和PasCI可以增强LVAD前风险分层,帮助心脏移植决策.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
343
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343
01:30Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
01:22Heart Failure VI: Adjunct Therapies
263
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263